牛牛AI助理已提取核心訊息
AbbVie Inc. has successfully priced a multi-tranche offering of Senior Notes totaling $15 billion on February 22, 2024. The offering includes various maturities: $2.25 billion due 2027, $2.5 billion due 2029, $2 billion due 2031, $3 billion due 2034, $750 million due 2044, $3 billion due 2054, and $1.5 billion due 2064, with interest rates ranging from 4.800% to 5.500%. The trade date was February 22, 2024, with a settlement date set for February 26, 2024. The notes received ratings of A3 (Stable) from Moody's and A- (Stable) from Standard & Poor's. The offering was registered with the SEC and managed by a syndicate of banks, including Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, among others. The notes are expected to be delivered on a T+2 basis, with interest payments commencing on September 15, 2024. This strategic move by AbbVie aims to diversify its funding sources and extend its debt maturity profile.
AbbVie Inc. has successfully priced a multi-tranche offering of Senior Notes totaling $15 billion on February 22, 2024. The offering includes various maturities: $2.25 billion due 2027, $2.5 billion due 2029, $2 billion due 2031, $3 billion due 2034, $750 million due 2044, $3 billion due 2054, and $1.5 billion due 2064, with interest rates ranging from 4.800% to 5.500%. The trade date was February 22, 2024, with a settlement date set for February 26, 2024. The notes received ratings of A3 (Stable) from Moody's and A- (Stable) from Standard & Poor's. The offering was registered with the SEC and managed by a syndicate of banks, including Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, among others. The notes are expected to be delivered on a T+2 basis, with interest payments commencing on September 15, 2024. This strategic move by AbbVie aims to diversify its funding sources and extend its debt maturity profile.
艾伯維公司已於2024年2月22日成功對總額爲150億美元的多批優先票據進行了定價。此次發行包括各種到期日：2027年到期的22.5億美元、2029年到期的25億美元、2031年到期的20億美元、2034年到期的30億美元、2044年到期的7.5億美元、2054年到期的30億美元和2064年到期的15億美元，利率從4.800％到5.500％不等。交易日期爲2024年2月22日，結算日期定爲2024年2月26日。這些票據獲得穆迪的A3（穩定）評級，標準普爾的評級爲A-（穩定）。此次發行已在美國證券交易委員會註冊，由包括摩根士丹利、摩根大通、美銀證券和花旗集團等在內的銀行集團管理。這些票據預計將在T+2基礎上交付，利息支付將於2024年9月15日開始。艾伯維的這一戰略舉措旨在分散其資金來源並擴大其債務到期日範圍。
艾伯維公司已於2024年2月22日成功對總額爲150億美元的多批優先票據進行了定價。此次發行包括各種到期日：2027年到期的22.5億美元、2029年到期的25億美元、2031年到期的20億美元、2034年到期的30億美元、2044年到期的7.5億美元、2054年到期的30億美元和2064年到期的15億美元，利率從4.800％到5.500％不等。交易日期爲2024年2月22日，結算日期定爲2024年2月26日。這些票據獲得穆迪的A3（穩定）評級，標準普爾的評級爲A-（穩定）。此次發行已在美國證券交易委員會註冊，由包括摩根士丹利、摩根大通、美銀證券和花旗集團等在內的銀行集團管理。這些票據預計將在T+2基礎上交付，利息支付將於2024年9月15日開始。艾伯維的這一戰略舉措旨在分散其資金來源並擴大其債務到期日範圍。
有用
沒用